USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE?
|
|
- John Ward
- 6 years ago
- Views:
Transcription
1 USING ANTIPSYCHOTICS TO TREAT THE BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)- WHAT IS THE EVIDENCE? Mugdha Thakur, MD Associate Professor of Psychiatry and Behavioral Sciences Duke University School of Medicine
2 PHARMACOLOGIC MANAGEMENT OF BPSD What is the evidence? Placebo controlled trials A priori defined primary outcome measure
3 ANTIPSYCHOTICS Positive efficacy studies: Haloperidol Risperidone Olanzapine Aripiprazole (quetiapine) Maglione (AHRQ) 2011
4 ATYPICAL ANTIPSYCHOTICS- EFFICACY Risperidone Olanzapine Quetiapine Aripiprazole Overall Psychosis ++ +/- +/- + Agitation / : moderate or high evidence of efficacy + : low or very low evidence of efficacy +/- : mixed results Schneider 2006, Maglione (AHRQ) 2011
5 ATYPICAL ANTIPSYCHOTICS- EFFICACY Maglione (AHRQ) 2011
6 ATYPICAL ANTIPSYCHOTICS: EFFICACY 15 trials, n = 3353 (drug) vs (placebo) Modest benefit Better results for patients in nursing homes Patients without psychotic symptoms Patients who were more severely cognitively impaired 1/3 dropped out Schneider 2006
7 TYPICAL ANTIPSYCHOTICS- EFFICACY Haldol Equivalent to atypical antipsychotics Maglione (AHRQ) 2011
8 ATYPICAL ANTIPSYCHOTICS: RISKS 2003: FDA warning CVAEs 2004: FDA warning all cause mortality 1.6 to 1.7 times placebo 10 week trial: 4.5% (drug) vs. 2.6% (placebo) NNT and NNH: For every 9 to 25 persons helped with these medications, there would be one death Other risks: Sedation, urinary symptoms, EPS, worsening cognition Jeste 2007
9 ATYPICAL ANTIPSYCHOTICS: RISKS CATIE- AD: No difference in time to discontinuation between risperidone, olanzapine, quetiapine, placebo Risperidone and Olanzapine better efficacy Quetiapine and Placebo better tolerability Schneider 2006
10 TYPICAL ANTIPSYCHOTICS: RISKS 6 large cohort studies comparing mortality for typical and atypical antipsychotics 4 found higher mortality with typical antipsychotics 2 found no difference FDA warning 2008 Maglione (AHRQ) 2011
11 ANTIPSYCHOTICS RISK Kales, 2012
12 ANTIPSYCHOTICS: DISCONTINUATION DART-AD: RCT probability of survival 12 m 24m 36m Antipsychotic 70% 46% 30% Placebo 77% 71% 59% No overall detrimental effect of stopping antipsychotic medication Deterioration in those with worse baseline BPSD (NPI > 15) Ballard 2008, 2009
13 ANTIPSYCHOTICS: DISCONTINUATION ADAD (Antipsychotic Discontinuation in AD) Trial 180 patients with probable AD, psychosis/ agitationaggression Outpatients and nursing homes 16 weeks of open label treatment with Risperidone: 62% response rate Responders randomized to continuation vs. placebo Devanand 2012
14 ANTIPSYCHOTICS: DISCONTINUATION Relapse rate at 16 weeks Placebo: 60% Risperidone: 33% Devanand 2012
15 ANTIPSYCHOTICS: DISCONTINUATION Relapse Rate at 32 weeks Placebo: 48% Risperidone: 15% Devanand 2012
16 CHOLINESTERASE INHIBITORS CALM-AD Donepezil = Placebo Systematic review 14 studies (9 with Donepezil), median 24 weeks Low NPI scores at baseline BPSD was secondary outcome in most studies 3 studies found modest statistical difference in NPI scores between drug and placebo Lewy Body Disease Rivastigmine > Placebo Howard 2007, Rodda 2009, McKeith 2000
17 MEMANTINE No prospective placebo controlled trials for treatment of BPSD Pooled retrospective analysis of 3 trials 6 months 60% patients had agitation/ aggression (NPI) Memantine > Placebo Wilcock 2008
18 SELECTIVE SEROTONIN REUPTAKE INHIBITORS Cochrane Review 5 studies comparing SSRIs to placebo 2 studies showing some benefit (sertraline, citalopram) No difference in rates of withdrawal between SSRIs and placebo Seitz 2011
19 MOOD STABILIZERS Carbamazepine ( mg) > Placebo More ataxia, disorientation, hallucinations Tariot 1998, Olin 2001 Divalproex/ Valproate ( mg) = Placebo Porsteinsson 2001, Sival 2002, Tariot 2001, Tariot 2005 Tariot 2001 trial (secondary mania) discontinued due to excessive dropouts in drug group compared to placebo
20 MOOD STABLILIZERS- SAFETY Mortality data Prophylaxis with VPA to prevent behavioral symptoms not effective VPA causes increased brain atrophy and hippocampal atrophy over 1 year of treatment Kales 2012, Fleisher 2011, Tariot 2011, Sandson 2006
21 Lebert 2004, Teri 2000, Sultzer 1997 TRAZODONE Trazodone > Placebo in 26 FTD patients Trazodone (200mg) = Placebo = Haloperidol (1.8mg) = Behavior Management Training 34% subjects improved (N =147) Trazodone = Haloperidol in dementia
22 PROPRANOLOL Propranolol augmentation (106 mg) > Placebo (Peskind 2005) gains lost at 6 months Aggression/ agitation Case series (Shankle 1995) Case reports (Pauszek 1991, Gadbaw 1989, Weiler 1988) Peskind 2005
23 PAIN MANAGEMENT 8 weeks of pain protocol management > usual care 352 NH patients with moderate to severe dementia and behavioral disturbance Tylenol, morphine, buprenorphine patch, pregabalin Husebo 2011
24 PRAZOSIN Prazosin > Placebo 22 subjects, 8 weeks 6 mg daily (2mg qam + 4 mg qpm) Starting dose of 1 mg, titrated up by 1-2 mg q 3-7 days Excluded SBP < 110 mm Hg, orthostatic Almost 50% dropout rate Post mortem studies of AD patients show aggressive behavior significantly correlated with alpha1 adrenoreceptor count Wang 2009, Sharp 2007
25 BENZODIAZEPINES No placebo controlled trials in BPSD Active comparator trials IM Olanzapine = IM Lorazepam > Placebo for acute agitation (Meehan 2002) Oxazepam = Haloperidol = Diphenhydramine (Coccaro 1990) Lorazepam = Alprazolam (Ancill 1991)
26 HORMONE THERAPY Transdermal estrogen 100 mcg/ d = Placebo 8 weeks, n = 27 Rebound increase in aggression on removal of patches Hall 2005
27 SUMMARY OF EVIDENCE Evidence for efficacy in the short term exists for: Antipsychotics Pain Management SSRIs Trazodone (FTD) Propranolol Prazosin Carbamazepine Cholinesterase Inhibitors (LBD) All drug treatments are off label, No FDA approved treatments
28 LIMITATIONS OF EVIDENCE Subtypes of dementia lumped together Behavioral symptoms lumped together What is placebo effect?
29 THANK YOU
11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease
Disclosures Behavioral Management of Persons with Alzheimer s Disease Wisconsin Association of Medical Directors November 17, 2016 Art Walaszek, M.D. Professor of Psychiatry UW School of Medicine & Public
More informationManagement of Agitation in Dementia. Kimberly Triplett Ferguson, MS4
Management of Agitation in Dementia Kimberly Triplett Ferguson, MS4 Objectives 1. Review recommended evaluation of agitated patients with dementia. 2. Discuss evidence concerning nonpharmacologic management.
More informationPsychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias. Aaron H. Kaufman, MD
Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, MD Psychiatric and Behavioral Symptoms in Alzheimer s and Other Dementias Aaron H. Kaufman, M.D. Health Sciences
More informationTreatment of behavioral and psychological symptoms of dementia: a systematic review
Psychiatr. Pol. 2016; 50(4): 679 715 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/64477 Treatment of behavioral and psychological symptoms
More informationOptimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches
Optimal Management of Challenging Behaviours in Dementia: An Update on Pharmacologic and Non-Pharmacologic Approaches Andrea Iaboni, MD, DPhil, FRCPC Toronto Rehab Institute, UHN Learning objectives Recognize
More informationImproving Antipsychotic Appropriateness in Dementia Patients. Disclosures. The Challenge 4/21/2014
Improving Antipsychotic Appropriateness in Dementia Patients Ryan Carnahan, Pharm.D., M.S., BCPP Associate Professor (Clinical) The University of Iowa College of Public Health Department of Epidemiology
More informationImproving Antipsychotic Appropriateness in Dementia Patients. Disclosures
Improving Antipsychotic Appropriateness in Dementia Patients Ryan Carnahan, Pharm.D., M.S., BCPP Assistant Professor (Clinical) The University of Iowa College of Public Health Department of Epidemiology
More informationMANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA
MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS OF DEMENTIA Dr. Dallas Seitz MD PhD FRCPC Associate Professor and Division Chair, Division of Geriatric Psychiatry Department of Psychiatry, Queen s University President,
More informationANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good?
ANTIPSYCHOTICS IN LONG TERM CARE: Are We Doing More Harm than Good? STEPHANIE M. OZALAS, PHARMD, BCPS, BCGP VA MARYLAND HEALTH CARE SYSTEM BALTIMORE, MD DISCLOSURES Off-label use of medications will be
More informationMEDICATIONS IN MANAGING DIFFICULT BEHAVIORS
MEDICATIONS IN MANAGING DIFFICULT BEHAVIORS A REALITY CHECK reality check Noun informal an occasion on which one is reminded of the state of things in the real world. ROBERT LACOSTE, MD MEDICAL DIRECTOR,
More informationDisclosure. Speaker Bureaus. Grant Support. Pfizer Forest Norvartis. Pan American Health Organization/WHO NIA HRSA
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
More informationBEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS IN DEMENTIA Unmet needs What might be your behavioural response to this experience? Content Definition What are BPSD? Prevalence How common are they? Aetiological
More informationAntipsychotic Medications
TRAIL: Team Review of EVIDENCE REVIEW & RECOMMENDATIONS FOR LTC Behavioural and psychological symptoms of dementia (BPSD) refer to the non-cognitive symptoms of disturbed perception, thought content, mood
More informationPsychotropic Strategies Handout Package
Psychotropic Strategies Handout Package Psychotropic Strategies Learning Objectives Utilize all clinical information available Assess the patient s overall condition this is essential Basic Principles
More informationPsychosis and Agitation in Dementia
Psychosis and Agitation in Dementia Dilip V. Jeste, MD Estelle & Edgar Levi Chair in Aging, Director, Stein Institute for Research on Aging, Distinguished Professor of Psychiatry & Neurosciences, University
More informationNeurocognitive Disorders Research to Emerging Therapies
Neurocognitive Disorders Research to Emerging Therapies Edward Huey, MD Assistant Professor of Psychiatry and Neurology The Taub Institute for Research on Alzheimer s Disease and the Aging Brain Columbia
More informationPharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital
Pharmacological Treatment of Behavioural and Psychological Symptoms of Dementia (BPSD) Gurdeep K Major St. Charles Hospital with thanks to Jonathan Cavan for his input Aims Define BPSD and common symptoms
More informationAntipsychotic use in dementia: a systematic review of benefits and risks from metaanalyses
658463TAJ0010.1177/2040622316658463Therapeutic Advances in Chronic DiseaseRR Tampi, DJ Tampi research-article2016 Therapeutic Advances in Chronic Disease Original Research Antipsychotic use in dementia:
More informationDEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
More informationPsychotropic Medication Use in Dementia
Psychotropic Medication Use in Dementia Marie A DeWitt, MD Diplomate of the American Board of Psychiatry and Neurology, Specialization in Psychiatry & Subspecialization in Geriatric Psychiatry Staff Physician,
More informationPharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review
International Psychogeriatrics (2013), 25:2, 185203 C International Psychogeriatric Association 2012.The online version of this article is published within an Open Access environment subject to the conditions
More informationDEMENTIA AND MEDICATION
DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,
More informationPharmacological Treatment of Aggression in the Elderly
Pharmacological Treatment of Aggression in the Elderly Howard Fenn, MD Adjunct Clinical Associate Professor Department of Psychiatry and Behavioral Sciences Stanford University Self-Assessment Question
More informationEvaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director
Evaluation and Management of Agitation and Aggression in Dementia Joseph W. Shega, MD National Medical Director Objectives Differentiate between delirium, terminal restlessness, and dementia related agitation
More informationCognitive enhancers PINCH ME. Anticholinergic burden BPSD. Agitation, Aggression and antipsychotics
Cognitive enhancers PINCH ME Anticholinergic burden BPSD Agitation, Aggression and antipsychotics 2 types Cholinesterase inhibitors licensed for mild to moderate AD Donepezil Galantamine Rivastigmine also
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment
More informationNovember 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by
November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Major Neurocognitive Disorder: The Beginning and the End. Making the Diagnosis and Addressing Distressing Behavior W. Vaughn McCall, MD,
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan Pretest 1. Which of the following conditions is LEAST likely to benefit from emergency
More informationRestrained use of antipsychotic medications:
Balanced information for better care Restrained use of antipsychotic medications: Rational management of irrationality These drugs are commonly prescribed in conditions for which there is little evidence
More informationUp to 90% of people with dementia experience
Focus on CME at the University of Calgary Getting Aggressive with Dementia Adrienne Cohen, MD, BSc, FRCPC Presented at Behaviour Problems in the Elderly, video-audio conference, 2003 Up to 90% of people
More informationMedication alternatives for behavioural disturbance
Neurology 13 Medication alternatives for behavioural disturbance Many patients with dementia will in the later stages develop distressing behavioural symptoms. Antipsychotics are commonly used to treat
More informationUse of Psychotropic Medications in Older Adults with Dementia!
Use of Psychotropic Medications in Older Adults with Dementia! Deepa Pattani, PharmD, RPh Owner: PrevInteract Health Deepa.Pattani@PrevInteract.com 972-372-9775 About Me Deepa Pattani, PharmD, RPh with
More informationClinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease
Clinical Trial Designs for RCTs focussing on the Treatment of Agitation in people with Alzheimer s disease Professor Clive Ballard Dr Byron Creese University of Exeter, UK Guardian guide for 2018: Top
More informationAssessment and management of behavioral and psychological symptoms of dementia
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
More informationPharmacotherapy of Dementia Behaviors
This Clinical Resource gives subscribers additional insight related to the Recommendations published in June 2017 ~ Resource #330601 Pharmacotherapy of Dementia Behaviors (Also see our chart specific to
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationAntipsychotics for Dementia Under Control or Over-Prescribed?
Antipsychotics for Dementia Under Control or Over-Prescribed? Nathaniel Hedrick, PharmD ProCare HospiceCare, Manager of Clinical Services Learning Objectives Summarize the disease progression and most
More informationThe treatment of behavioral disturbances and psychosis associated with dementia
Psychiatr. Pol. 2016; 50(2): 311 322 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/pp/60904 The treatment of behavioral disturbances and psychosis
More informationNeuroPharmac Journal ISSN: Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M.
ISSNISSN ISSN: 2456-3927 NeuroPharmac Journal Alzheimer s Disease: Pharmacotherapy of noncognitive symptoms Aslam Pathan; Abdulrahman M. Alshahrani www. neuropharmac.com Jan-April 2018, Volume 3, Issue
More information11/11/2016. Relevant Disclosures Current or past. Outline
Management of Agitation in Dementia 2016 Update Constantine G. Lyketsos, MD, MHS Interim Chair of Psychiatry, Johns Hopkins Medicine Elizabeth Plank Althouse Professor, Johns Hopkins University kostas@jhmi.edu
More informationBEHAVIORAL PROBLEMS IN DEMENTIA
BEHAVIORAL PROBLEMS IN DEMENTIA CLINICAL FEATURES Particularly as dementia progresses, psychiatric symptoms may develop that resemble discrete mental disorders such as depression or mania The course and
More informationManagement of the Acutely Agitated Long Term Care Patient
Management of the Acutely Agitated Long Term Care Patient 80 60 Graying of the Population US Population Over Age 65 Millions of Persons 40 20 0 1900 1920 1940 1960 1980 1990 2010 2030 Year Defining Dementia
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationPlease Join Us. International Psychogeriatric Association. Dependency Ratio. Geriatric Psychiatry in the 21st Century: A Global Perspective
International Psychogeriatric Association Please Join Us Geriatric Psychiatry in the 21st Century: A Global Perspective Jacobo Mintzer M.D. Executive Director Roper Saint Frances Clinical and Biotechnology
More informationAppropriate diagnoses for antipsychotics
Nancy M. Birtley, DNP, APRN, PMHCNS BC, PMHNP BC Owner, Psychiatric Consultation Services Assistant Teaching Professor University of Missouri, Columbia 1 Appropriate diagnoses for antipsychotics Schizophrenia/Schizoaffective
More informationFrom Neurodevelopment to Neurodegeneration: Behavioral Issues
From Neurodevelopment to Neurodegeneration: Behavioral Issues Amer M. Burhan, MBChB, FRCPC Associate Professor and Chair Geriatric Psychiatry at Western U Objectives Discuss factors that contribute to
More informationMORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE
MORTALITY ASSOCIATED WITH USE OF ANTIPSYCHOTICS IN DEMENTIA: REVIEWING THE EVIDENCE KRISTA L. LANCTÔT, PHD PROFESSOR OF PSYCHIATRY AND PHARMACOLOGY, UNIVERSITY OF TORONTO; SENIOR SCIENTIST, HURVITZ BRAIN
More informationI received help from Bosch Health Care
John Kasckow, MD, PhD VA Pittsburgh Health Care System Western Psychiatric Institute and Clinic, UPMC VA Pittsburgh Health Care System I received help from Bosch Health Care 1 Diagnoses of Interest Early
More informationAppendix N: Research recommendations
Appendix N: recommendations N.1 First-line treatment of motor symptoms recommendation 1 Interventions What is the effectiveness of initial levodopa monotherapy versus initial levodopa-dopamine agonist
More informationOpinion statement. Introduction. Cognitive Disorders (M Geschwind, Section Editor)
Current Treatment Options in Neurology DOI 10.1007/s11940-012-0166-9 Cognitive Disorders (M Geschwind, Section Editor) Treatment of Behavioral and Psychological Symptoms of Alzheimer s Disease Anne Corbett,
More informationPharmacologic Management of Mood and Behavioral Changes in
Pharmacologic Management of Mood and Behavioral Changes in Dementia James E. Galvin, MD, MPH Professor of Neurology and Psychiatry New York University Langone Medical Center CADASIL MRI scan showing leukoencephalopathyon
More informationPiecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder
Piecing the Puzzle Together: Pharmacologic Approaches to Behavioral Management in Autism Spectrum Disorder Hannah Sauer, PharmD PGY1 Pediatric Pharmacy Resident Mayo Clinic 2015 MFMER slide-1 Objectives
More informationDelirium. A Plan to Reduce Use of Restraints. David Wensel DO, FAAHPM Medical Director Midland Care
Delirium A Plan to Reduce Use of Restraints David Wensel DO, FAAHPM Medical Director Midland Care Objectives Define delirium Describe pathophysiology of delirium Understand most common etiologies Define
More informationDementia: Managing Difficult Behaviors. No conflicts of interest. Off-label medication use will be discussed during this talk.
Dementia: Managing Difficult Behaviors No conflicts of interest. Off-label medication use will be discussed during this talk. 1 Types of Neurocognitive Disorder Alzheimer s Disease Vascular Frontotemporal
More informationEffective Health Care Program
Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Antipsychotics medications are approved by the
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationDiscontinuing Dementia Medications Case April Patient Case
Discontinuing Dementia Medications Case April 2017 Patient Case MJ is an 86 year-old female with a primary diagnosis of Alzheimer s disease and history of anemia, cystitis, depression, Type II DM, HTN,
More informationThings You Might Not Know About Psychotropic Medications But Wish You Did
Things You Might Not Know About Psychotropic Medications But Wish You Did John E. Dunne, MD December 3, 2016 PAL Conference Conflicts of Interest None to report I am employed by Seattle Children s and
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationMedications for treating people with dementia: summary of evidence on cost-effectiveness
Medications for treating people with dementia: summary of evidence on cost-effectiveness Martin Knapp, A-La Park and Alistair Burns PSSRU, London School of Economics and Political Science v4 23 July 2017
More informationMedications and Non-Pharma Approaches to Treatment. David J. Irwin, MD Penn Frontotemporal Degeneration Center
Medications and Non-Pharma Approaches to Treatment David J. Irwin, MD Penn Frontotemporal Degeneration Center Outline Non-Pharmacological Treatment Strategies Behavior Language Motor Supportive Care Check-points
More informationAntipsychotic Medications in the Treatment of Dementia with Behavior Disturbance
Antipsychotic Medications in the Treatment of Dementia with Behavior Disturbance American Association for Geriatric Psychiatry Los Angeles, CA March 2013 Maureen C. Nash, MD, MS, FAPA Medical Director,
More informationAgita&on/Aggression in Elderly: What works. G. Michael Allan Professor, Dept of Family, U of A. Director, Evidence & CPD Program, ACFP
Agita&on/Aggression in Elderly: What works G. Michael Allan Professor, Dept of Family, U of A. Director, Evidence & CPD Program, ACFP Background: Agita6on in Demen6a Demen&a can > agita&on and violent
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSCHIZOPHRENIA IN OLD AGE
SCHIZOPHRENIA IN OLD AGE Maria Sonnack, MPAS, PA C Department of Behavioral Health Broadlawns Medical Center Ms. Sonnack has no relevant financial conflicts with commercial interests to disclose. Objectives
More informationManagement of Behavioral and Psychological Symptoms in People with Dementia Living in Care Homes: A UK Perspective
Management of Behavioral and Psychological Symptoms in People with Dementia Living in Care Homes: A UK Perspective Clive Ballard Professor of Age Related Diseases, King s College London And Director of
More informationPharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018
Pharmacological Treatments for Neuropsychiatric Symptoms in Dementia 3/22/2018 Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology UNTHSC Center for Geriatrics 855 Montgomery Street, PCC 4, Ft.
More informationSt Francis Hospice. How common is it? How is it prevented? 10/07/2017. What is delirium? DSM IV criteria. Delirium vs Dementia.
What is delirium? DSM IV criteria St Francis Hospice Dr Hilary Kinsler Disturbance of consciousness reduced clarity of awareness of the environment Change in cognition memory deficit, disorientation, language
More information2/12/2016. Drugs and Dementia in the Hospice Patient. Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources
Drugs and Dementia in the Hospice Patient Jim Joyner, Pharm.D., C.G.P. Director of Clinical Operations Outcome Resources 1 Drug Therapy: Targeted at Symptoms Cognitive: Impaired abstract thinking Impaired
More informationClinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India
Indian J Psychiatry. 2009 Oct-Dec;; 51(4): 272 275. doi: 10.4103/0019-5545.58292 PMCID: PMC2802374 Clinical practice with antidementia and antipsychotic drugs: Audit from a geriatric clinic in India 1
More informationShriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences
Shriti Patel, MD Associate Program Director of Psychiatry Residency Eastern Virginia Medical School Department of Psychiatry and Behavioral Sciences Disclosures Board Certified in Adult and Geriatric Psychiatry
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationCambridge University Press Effective Treatments in Psychiatry Peter Tyrer and Kenneth R. Silk Excerpt More information
Organic disorders 1 Delirium Based on Delirium by Laura Gage and David K. Conn in Effective Treatments in Psychiatry, Cambridge University Press, 2008 Introduction Delirium needs treatment for both its
More informationManagement of agitation and aggression associated with Alzheimer disease
Management of agitation and aggression associated with Alzheimer disease Clive G. Ballard, Serge Gauthier, Jeffrey L. Cummings, Henry Brodaty, George T. Grossberg, Philippe Robert and Constantine G. Lyketsos
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationAssessment and management of behavioral. B ehavior al and psychological symptoms of dementia are STATE OF THE ART REVIEW
Assessment and management of behavioral and psychological symptoms of dementia Helen C Kales, 1 2 3 Laura N Gitlin, 4 5 6 Constantine G Lyketsos 7 1 Section of Geriatric Psychiatry, Department of Psychiatry,
More informationALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY
ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100
More informationBehavioral and Psychological Symptoms of dementia (BPSD)
Behavioral and Psychological Symptoms of dementia (BPSD) Chris Collins - Old Age Psychiatrist, Christchurch chris.collins@cdhb.health.nz Approaching BPSD: the right mindset Assessment Non-drug management
More informationDrugs used to relieve behavioural and psychological symptoms in dementia
alzheimers.org.uk Drugs used to relieve behavioural and psychological symptoms in dementia People with dementia may develop behavioural and psychological symptoms including restlessness, aggression, delusions,
More informationAtypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study
Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study Stewart G. Albert, MD, George T. Grossberg, MD, Papan J. Thaipisuttikul,
More informationThe prevalence of dementia increases from. Pharmacological management of behavioural disturbance in patients with dementia. Dementia.
Dementia Pharmacological management of behavioural disturbance in patients with dementia Management of behavioural disturbance in the setting of dementia can be challenging. There are many potential causes
More informationApproach to the Management of Dementia-Related Behavioural Problems
Dementia Approach to the Management of Dementia-Related Behavioural Problems Michael J. Passmore, MD, FRCPC, Clinical Assistant Professor, Department of Psychiatry, Geriatric Psychiatry Program, University
More information10/5/2017. BEHAVIORAL and PSYCHOLOGICAL SYMPTOMS in DEMENTIA (BPSD) Dr. Shah MD, MPH Braodlawns Medical Center DISCLOSURE
1 BEHAVIORAL and PSYCHOLOGICAL SYMPTOMS in DEMENTIA (BPSD) Dr. Shah MD, MPH Braodlawns Medical Center DISCLOSURE 2 Dr. Shah has no relevant conflicts with commercial interests to disclose. OBJECTIVES 3
More informationCognitive disorders. Dr S. Mashaphu Department of Psychiatry
Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during
More informationSwitching antipsychotics: Basing practice on pharmacology & pharmacokinetics
Switching antipsychotics: Basing practice on pharmacology & pharmacokinetics John Donoghue Liverpool L imagination est plus important que le savoir Albert Einstein Switching Antipsychotics: Objectives
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationThe Psychopharmacology of Alzheimer s Disease. Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school
The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationGuidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care
Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia (BPSD) Summary document for Primary Care Guidelines for the Management of Behavioural and Psychological Symptoms of Dementia
More informationThe Agitated. Older Patient: old. What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003
Focus on CME at Queen s University Focus on CME at Queen s University The Agitated The Older Patient: What To Do? Michelle Gibson, MD, CCFP Presented at Brockville General Hospital Rounds, May 2003 Both
More informationAtivan and geodon compatibility
P ford residence southampton, ny Ativan and geodon compatibility In this case, a patient developed severe hypotension (66/30 mm Hg) after receiving intramuscular olanzapine and intramuscular lorazepam
More informationManagement of the behavioral and psychological symptoms of dementia
REVIEW Management of the behavioral and psychological symptoms of dementia Elizabeth C Hersch Sharon Falzgraf VA Puget Sound Health Care System, Tacoma, Washington, USA Correspondence: Elizabeth C Hersch
More informationManual of Clinical Psychopharmacology
Manual of Clinical Psychopharmacology Fourth Edition Alan F. Schatzberg, M.D. Kenneth T. Norris, Jr., Professor and Chairman, Department of Psychiatry and Behavioral Sciences, Stanford University School
More informationA Basic Approach to Mood and Anxiety Disorders in the Elderly
A Basic Approach to Mood and Anxiety Disorders in the Elderly November 1 2013 Sarah Colman MD FRCPC Clinical Fellow, Geriatric Psychiatry Mount Sinai Hospital, University of Toronto Disclosure No conflict
More informationProfessor Tony Holland, Department of Psychiatry, University of Cambridge
INFORMATION SHEET The Use of Medication for Challenging Behaviour Professor Tony Holland, Department of Psychiatry, University of Cambridge Introduction Challenging behaviours displayed by people with
More informationDelirium Monograph - Update, Spring 2014
Delirium Monograph - Update, Spring 2014 Since publication of the APM monograph on Delirium in January 2012, three structured reviews have been published adding data relevant to the practice of identification,
More informationAntipsychotics in Dementia
Antipsychotics in Dementia What s all the fuss? Judy MacDonald RPh BSc Pharm Dr. Ashok Krishnamoorthy MD MRCPsych FRCPC ABAM MS (Neuro Psych) Learning Objectives Recognize common behavioural & psychological
More informationAntipsychotic Use in the Elderly
Antipsychotic Use in the Elderly Presented by: Fatima M. Ali, PharmD, RPh, BCPS Clinical Consultant Pharmacist MediSystem Pharmacy, Kingston Originally Prepared by: Nicole Tisi BScPhm, RPh ACPR Disclosure
More informationMedicine Related Falls Risk Assessment Tool (MRFRAT)
Medicine Related Falls Risk Assessment Tool (MRFRAT) The Medicine Related Falls Risk Assessment tool (MRFRAT) in Appendix 1 is designed to help identify patients at risk of falls due to their current medicine
More informationOrganization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit
Organization: Sheppard Pratt Health System Solution Title: Lean Methodology: Appropriate Antipsychotic Use on an Inpatient Dementia Unit Problem: For dementia patients, antipsychotic medications are prescribed
More information